Subscribe for free to the America First Report newsletter.
STORY AT-A-GLANCE
- The U.S. Centers for Disease Control and Prevention issued a warning about the potential for COVID-19 rebound after Paxlovid treatment
- Dr. Anthony Fauci took Paxlovid for COVID-19, tested negative, then developed worsened symptoms, known as COVID-19 rebound; he then took a second course of the drug
- People who take Paxlovid can still transmit COVID-19 to others, even if they’re asymptomatic
- Two separate studies suggest Paxlovid is causing SARS-CoV-2 to mutate and develop resistance to the drug
- Despite the many questions regarding Paxlovid’s association with rebound infections and mutations, Pfizer is moving ahead and seeking full approval of the drug from the FDA
Pfizer’s Paxlovid was granted emergency use authorization to treat mild to moderate COVID-19 in December 2021.1 The drug consists of nirmatrelvir tablets — the antiviral component — and ritonavir tablets, which are intended to slow the breakdown of nirmatrelvir.2
What started out as a slow rollout — only 40,000 or fewer prescriptions were written for the drug in the U.S. each week through April 2022 — has gained steam, with more than 160,000 Paxlovid prescriptions now being issued each week.3 As of June 30, 2022, 1.6 million courses of Paxlovid have been prescribed in the U.S. since its emergency use approval in December.4
Yet, this increase in prescribing could be contributing to one of the significant downfalls of the drug — the creation of selective pressure on SARS-CoV-2, which promotes mutations that could make it resistant to the drug.5 The U.S. Centers for Disease Control and Prevention also issued a warning to health care providers and public health departments about the potential for COVID-19 rebound after Paxlovid treatment.6
This recently happened to Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), who experienced a return of COVID-19 symptoms after taking Paxlovid. He then took a second course of the drug, which could trigger even more mutations in the virus.
Paxlovid Triggers Fauci’s COVID-19 Rebound
Fauci said he tested positive for COVID-19, with only minimal symptoms. As his symptoms increased, he took Paxlovid for five days, after which he tested negative for three consecutive days. On the fourth day of testing, he tested positive for COVID-19 again, with symptoms worse off than they were the first time.
“It was sort of what people are referring to as a Paxlovid rebound,” he said. “… Over the next day or so I started to feel really poorly, much worse than in the first go around.”7 He was then prescribed a second course of Paxlovid.
On June 30, he stated, “I went back on Paxlovid, and right now I am on my fourth day of a five-day course of my second course of Paxlovid. Fortunately, I feel reasonably good. I mean, I’m not completely without symptoms, but I certainly don’t feel acutely ill.”8 In the CDC’s health advisory regarding COVID-19 rebound after Paxlovid treatment it’s stated:9
“Recent case reports document that some patients with normal immune response who have completed a 5-day course of Paxlovid for laboratory-confirmed infection and have recovered can experience recurrent illness 2 to 8 days later, including patients who have been vaccinated and/or boosted …
These cases of COVID-19 rebound had negative test results after Paxlovid treatment and had subsequent positive viral antigen and/or reverse transcriptase polymerase chain reaction (RT-PCR) testing.”
COVID-19 Still Spreads During Paxlovid Rebound
People who take Paxlovid can still transmit COVID-19 to others, even if they’re asymptomatic, according to a preprint study.10 Study author Dr. Michael Charness of the Veterans Administration Medical Center in Boston told CNN, “People who experience rebound are at risk of transmitting to other people, even though they’re outside what people accept as the usual window for being able to transmit.”11
The CDC12 and Pfizer13 have suggested that sometimes COVID-19 naturally comes back after a person tests negative, implying that COVID-19 rebound is spontaneous and not necessarily linked to Paxlovid. However, Charness and colleagues didn’t find this to be the case. When they analyzed 1,000 cases of COVID-19 diagnosed among members of the National Basketball Association — none of whom took Paxlovid — no cases of COVID-19 rebound were found.14
Research published in Clinical Infectious Diseases15 looked into why Paxlovid may be leading to rebound symptoms and suggests it could be the result of insufficient exposure to the drug.16 “Not enough of the drug was getting to infected cells to stop all viral replication,” UC San Diego Health reported. “They suggested this may be due to the drug being metabolized more quickly in some individuals or that the drug needs to be delivered over a longer treatment duration.”17
Pfizer Seeks FDA Approval for Paxlovid
Despite the many questions regarding Paxlovid’s association with rebound infections, Pfizer is moving ahead and seeking full approval of the drug from the FDA.18 The drug’s emergency use authorization restricts who the drug can be sold and marketed to. Once full FDA approval is granted, Pfizer can market the drug directly to consumers.
Paxlovid’s emergency use authorization allows it to be prescribed for adults and children ages 12 and older who are at high risk for progression to severe COVID-19.19 Pfizer estimates that up to 60% of the U.S. population meets these criteria and has at least one risk factor for severe illness, such as obesity or diabetes, making them eligible for the drug.20
However, concerns have risen over whether Paxlovid, which is said to cut the risk of hospitalization or death by 86% in high-risk patients, when taken within five days of symptoms starting,21 is effective in people who are not high-risk.
In fact, Pfizer stopped a large trial of Paxlovid in standard-risk patients because it didn’t show significant protection against hospitalization or death in this group.22 According to a news release from Pfizer:23
“In previously reported interim analyses, the company disclosed that the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met, and a non-significant 70% relative risk reduction was observed in the key secondary endpoint of hospitalization or death (treatment arm: 3/428; placebo: 10/426).
An updated analysis from 1,153 patients enrolled through December 2021 showed a non-significant 51% relative risk reduction (treatment arm: 5/576; placebo: 10/569). A sub-group analysis of 721 vaccinated adults with at least one risk factor for progression to severe COVID-19 showed a non-significant 57% relative risk reduction in hospitalization or death (treatment arm: 3/361; placebo: 7/360).”
Is Paxlovid Triggering SARS-CoV-2 Mutations?
Initial reports have suggested that SARS-CoV-2 is not mutating and becoming resistant to Paxlovid, but some experts believe it’s only a matter of time before this occurs — and emerging research suggests it’s already happened.
David Ho, a virologist at the Aaron Diamond AIDS Research Center at Columbia University, was among the first to document resistance mutations in HIV 30 years ago and believes the same may be coming with SARS-CoV-2.24 He’s also experienced post-Paxlovid COVID-19 rebound firsthand. Bloomberg reported:25
“Ho said he came down with COVID on April 6 … His doctor prescribed Paxlovid, and within days of taking it, his symptoms dissipated and tests turned negative. But 10 days after first getting sick, the symptoms returned and his tests turned positive for another two days.
Ho said he sequenced his own virus and found that both infections were from the same strain, confirming that the virus had not mutated and become resistant to Paxlovid. A second family member who also got sick around the same time also had post-Paxlovid rebound in symptoms and virus, Ho says.
‘It surprised the heck out of me,’ he said. ‘Up until that point I had not heard of such cases elsewhere.’ While the reasons for the rebound are still unclear, Ho theorizes that it may occur when a small proportion of virus-infected cells may remain viable and resume pumping out viral progeny once treatment stops.”
Studies Show COVID-19 Virus Developing Paxlovid Resistance
Two separate studies cultured SARS-CoV-2 in a lab and exposed it to low levels of nirmatrelvir, which would kill some, but not all, of the virus. “Such tests are meant to simulate what might happen in an infected person who doesn’t take the whole regimen of the drug or an immunocompromised patient who has trouble clearing the virus,” Science reported.26
One of the studies revealed that SARS-CoV-2 developed three mutations after 12 rounds of nirmatrelvir treatment — “at positions 50, 166 and 167 in the string of amino acids that make up MPRO.”27 The mutations amounted to a 20-fold reduction in the virus’ susceptibility to nirmatrelvir.28 The other study29 also found mutations at positions 50 and 166, revealing that when they occurred together, SARS-CoV-2 became 80 times less susceptible to nirmatrelvir. According to the study:30
“Reverse genetic studies in a homologous infectious cell culture system revealed up to 80-fold resistance conferred by the combination of substitutions L50F and E166V. Resistant variants had high fitness increasing the likelihood of occurrence and spread of resistance.”
Lead study author Judith Margarete Gottwein with the University of Copenhagen told Science, “This tells us what mutations we should be looking for [in patients].”31 Ho, who was not involved in these studies, agreed that it appeared mutations were an inevitable outcome.
He told Science, “when you put pressure on the virus it escapes … Given the amount of infections out there, it’s going to come.”32 It’s also completely unknown what may happen when two courses of Paxlovid are taken in quick succession to treat COVID-19 rebound — as occurred with Fauci. It’s possible that ever-mutating COVID-19 variants could be created.
Other antivirals on the market to treat COVID-19 have also led to concerns over mutations. Molnupiravir (sold under the brand name Lagevrio) was developed by Merck and Ridgeback Therapeutics and approved by the FDA for emergency use December 23, 2021, for high-risk patients with mild to moderate COVID symptoms.
However, not only might it contribute to cancer and birth defects, it may also supercharge the rate at which the virus mutates inside the patient, resulting in newer and more resistant variants.33
Other Early COVID-19 Treatments Ignored
Using drugs that cause high rates of organ failure, like remdesivir, and drugs that cause the virus to rebound with a vengeance, like Paxlovid, and potentially trigger mutations don’t seem to be in the best interest of public health. The fact that U.S. health authorities have focused on these drugs to the exclusion of all others, including older drugs with high rates of effectiveness and superior safety profiles, sends a very disturbing message.
An investigation by Cornell University, posted on the University’s preprint server January 20, 2022, found ivermectin outperformed 10 other drugs against COVID-19, making it the most effective against the Omicron variant.34 It even outperformed Paxlovid, yet it’s been vilified by health officials and mainstream media.
Remdesivir costs between $2,340 and $3,120,35 and nirmatrelvir costs $529 per five-day treatment,36 while the average treatment cost for ivermectin is $58.37 Do you think this has anything to do with ivermectin’s vilification?
Preparedness Resources for “Late Preppers”
* Subscribe to The Late Prepper newsletter
* Purchase preparedness supplies
* Inquire about precious metals
Paxlovid alone has cost U.S. taxpayers $5.29 billion,38 while safe and less expensive options exist. Dr. Pierre Kory, who is part of the group that formed the Front Line COVID-19 Critical Care Working Group (FLCCC) to advance early treatments for COVID-19, pleaded with the U.S. government early on in the pandemic to review the expansive data on ivermectin to prevent COVID-19, keep those with early symptoms from progressing and help critically ill patients recover — to no avail.39,40
However, if you’d like to learn more about its potential uses for SARS-CoV-2, FLCCC’s I-MASK+ protocol can be downloaded in full,41 giving you step-by-step instructions on how to prevent and treat the early symptoms of COVID-19.
- 1, 19 U.S. FDA December 22, 2021
- 2, 3, 5, 22, 24, 26, 28, 31, 32 Science June 29, 2022
- 4, 18, 20, 21 Forbes June 30, 2022
- 6 U.S. CDC May 24, 2022
- 7, 8 CNN June 30, 2022
- 9, 12 U.S. CDC, COVID-19 Rebound After Paxlovid Treatment May 24, 2022
- 10 Research Square May 23, 2022
- 11, 13, 14 CNN May 31, 2022
- 15 Clinical Infectious Diseases June 20, 2022
- 16, 17 UC San Diego Health June 21, 2022
- 23 Pfizer June 14, 2022
- 25 Bloomberg April 29, 2022 (Archived)
- 27, 29, 30 bioRxiv June 7, 2022
- 33 Revyuh May 1, 2022
- 34 Cornell University, January 20, 2022
- 35 AJMC June 29, 2020
- 36 Precision Vaccinations, November 19, 2021
- 37 JAMA 2022;327(6):584-587
- 38 Reuters November 18, 2021
- 39 FLCCC Alliance, Ivermectin & COVID-19
- 40 Mountain Home May 1, 2021
- 41 FLCCC Alliance, I-Mask+
Covid variant BA.5 is spreading. It appears milder but much more contagious and evades natural immunity. Best to boost your immune system with new Z-Dtox and Z-Stack nutraceuticals from our dear friend, the late Dr. Vladimir Zelenko.
HIV-1 protease inhibitors (-navir) have their best efficacy against retroviruses.
NS3/4A protease inhibitors (-previr) have their best efficacy against hepatitis C.
Papain-like protease (PLpro) inhibitors have had efficacy in vitro but never in vivo.
3C-like protease (3CLpro) inhibitors (-trelvir) are also known as nonstructural protein 5 (NSP5) inhibitors or main protease (Mpro) inhibitors:
https://en.wikipedia.org/wiki/Protease_inhibitor_(pharmacology)
Pfizer’s PF-07321332 (nirmatrelvir) is a 3CL protease inhibitor that breaks down too rapidly in the human bloodstream without the addition of ritonavir:
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-covid-treatment-paxlovid-fails-prevent-infection-household-members-2022-04-29/
Pfizer’s PF-07304814 (intravenous nirmatrelvir) is a 3CL protease inhibitor that was halted prematurely in the ACTIV-3 trial because of both bad side effects and lack of efficacy:
https://www.fiercebiotech.com/biotech/pfizer-a-rare-covid-19-setback-dumps-paxlovid-s-intravenous-sibling-to-leave-activ-3-future
Enanta’s EDP-235 is a 3CL protease inhibitor that does not require the addition of ritonavir:
https://www.marketwatch.com/story/enanta-filed-patent-infringement-suit-against-pfizer-over-paxlovid-271655846242
https://finance.yahoo.com/chart/ENTA
Todos Medical’s Tollovir is, like vitamin B12, a “natural” 3CL protease inhibitor:
https://finance.yahoo.com/chart/TOMDF
Ascletis’ ASC-11 (requires ritonavir), Everest Medicines’ EDDC-2214 (no ritonavir), Pardes Bio’s PBI-0451 (no ritonavir), Sorrento’s STI-1558 (no ritonavir), and Sohei Heptares’ SH-879 (no ritonavir) have now all been tested in lab animals:
https://pbs.twimg.com/media/FSO8gmVVsAEMr__.jpg:large
China’s Y180, which has about the same EC50 (in vitro efficacy) as Pfizer’s nirmatrelvir, is a 3CL protease inhibitor that does not require the addition of ritonavir:
https://www.nature.com/articles/s41564-022-01119-7
Zhongsheng Pharma’s RAY1216, which has about the same EC50 (in vitro efficacy) as Pfizer’s nirmatrelvir, is a 3CL protease inhibitor that does not require the addition of ritonavir:
https://www.yicaiglobal.com/news/zhongsheng-pharma-gains-after-its-oral-covid-19-drug-gets-go-ahead-for-clinical-trials
Simcere Pharma’s SIM0417, which has about the same EC50 (in vitro efficacy) as Pfizer’s nirmatrelvir, is a 3CL protease inhibitor that does not require the addition of ritonavir:
https://finance.yahoo.com/news/simcere-pharma-hk-2096-novel-034000468.html
Shionogi’s S-217622, which has now been named, Xocova (ensitrelvir), is a 3CL protease inhibitor that does not require the addition of ritonavir and has an excellent EC50 (in vitro efficacy) of 0.29μM to 0.50μM, which is far superior to Pfizer’s nirmatrelvir, which has an EC50 (in vitro efficacy) of 6.76μM to 14.81μM:
https://en.wikipedia.org/wiki/3C-like_protease#As_a_treatment_target
https://en.wikipedia.org/wiki/ensitrelvir
https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00117
https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c00117/asset/images/acs.jmedchem.2c00117.social.jpeg_v03
https://www.valdostadailytimes.com/news/business/new-data-for-shionogi-s-covid-19-once-daily-oral-antiviral-s-217622-show-rapid/article_2ffd9953-866d-56f8-b786-8be36f583d9f.html
https://www.india.com/news/world/covid-pill-shows-rapid-clearance-of-infection-japanese-pharma-firm-shionogi-5356016/
https://www.medrxiv.org/content/10.1101/2022.05.17.22275027v1.full
https://c19early.com/mukae.html
https://c19early.com/en
In the past, all HIV-1 protease inhibitors had their best efficacy against retroviruses and failed against RNA viruses. Kaletra (lopinavir plus ritonavir) is a combination of two HIV-1 protease inhibitors that had some efficacy against retroviruses but failed against RNA viruses:
https://www.sciencedirect.com/science/article/pii/S2095809920300631
https://www.tribuneindia.com/news/health/hiv-drugs-lopinavir-ritonavir-show-no-promise-for-covid-treatment-reveals-uks-recovery-trial-106659
https://www.medrxiv.org/content/10.1101/2020.07.23.20153932v1.full
https://pubmed.ncbi.nlm.nih.gov/33264556/
Pfizer’s 3CL protease inhibitor, PF-07321332 (nirmatrelvir), needs to be swallowed together with the HIV-1 protease inhibitor, ritonavir:
https://www.drugs.com/sfx/ritonavir-side-effects.html
https://www.drugs.com/comments/ritonavir/
Pfizer’s Paxlovid (nirmatrelvir plus ritonavir) comprises of 3 pills that need to be swallowed twice daily for never more than 5 days.
Shionogi’s Xocova (ensitrelvir) comprises of just 1 pill that needs to be swallowed once each day for 5 days.
In Emi Takashita’s in vitro study, Merck’s molnupiravir was 17.84 times more effective than Pfizer’s nirmatrelvir against the Delta variant and 29.56 times more effective than Pfizer’s nirmatrelvir against the Omicron variant. All 10 monoclonal antibody drugs in Emi Takashita’s Japanese in vitro study failed even more severely against the Omicron variant than Pfizer’s nirmatrelvir:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809508/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809508/table/t1/
https://igorchudov.substack.com/p/paxlovid-snake-oil-of-the-21st-century?
In the past, all HIV-1 protease inhibitors, including RITONAVIR, were cell-damaging pro-oxidants and had a long list of BAD SIDE EFFECTS (artery wall damage, arthralgia, bleeding among hemophiliacs, blood clots among normal people, bone damage, brain damage, dysgeusia, endocrine system damage, endoplasmic reticulum damage, fatty liver, gingivitis, Golgi damage, hair loss, hearing loss, heart damage, hyperlipidemia, hypertension, hypertriglyceridemia, insulin resistance, kidney damage, kidney stones, liver damage, metallic mouth, mitochondria damage, muscle damage, nervous system damage, oxidative stress, pancreatitis, sexual dysfunction, skin damage, vision loss):
https://h-i-v.net/treatment/protease-inhibitors
https://www.theatlantic.com/health/archive/2022/05/pfizer-paxlovid-covid-pill-side-effects/629772/
RITONAVIR causes platelet aggregation (blood clots):
https://www.aidsmap.com/news/apr-2002/protease-inhibitor-patients-higher-risk-thrombosis
https://www.sciencedirect.com/science/article/abs/pii/S0049384818304110
RITONAVIR causes bleeding in hemophiliacs, who can catch HIV or hepatitis from their frequent blood transfusions:
https://journals.lww.com/pidj/Fulltext/1998/10000/SPONTANEOUS_BLEEDING_ASSOCIATED_WITH_THE_USE_OF.21.aspx
RITONAVIR causes endothelial dysfunction (artery wall damage):
https://pharmrev.aspetjournals.org/content/pharmrev/73/3/924/F5.large.jpg
https://www.ahajournals.org/doi/10.1161/01.atv.0000034707.40046.02
https://www.ahajournals.org/cms/asset/8ff76415-3c4c-4264-a481-82fb7d04675c/jah35534-fig-0007.png
https://www.researchgate.net/publication/251478478_Pomegranate_Extract_Blocks_Ritonavir-Induced_Endothelial_Dysfunction_In_Porcine_Pulmonary_Arteries
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792423/
https://www.mdpi.com/1422-0067/20/2/294/htm
https://www.mdpi.com/ijms/ijms-20-00294/article_deploy/html/images/ijms-20-00294-g009.png
RITONAVIR causes vision loss (retina damage):
https://pubmed.ncbi.nlm.nih.gov/20966821/
https://www.aao.org/editors-choice/longterm-ritonavir-treatment-may-lead-to-retinal-p
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853367/
https://pubmed.ncbi.nlm.nih.gov/26555254/
https://pubmed.ncbi.nlm.nih.gov/27285286/
https://pubmed.ncbi.nlm.nih.gov/31046022/
https://www.sciencedirect.com/science/article/pii/S2451993619300957
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458545/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249001/
https://www.ijretina.com/index.php/ijretina/article/view/179
RITONAVIR causes hearing loss (inner ear damage):
https://pubmed.ncbi.nlm.nih.gov/11712105/
https://www.sciencedirect.com/science/article/pii/S1808869417301179
https://www.frontiersin.org/articles/10.3389/fneur.2021.725566/full
RITONAVIR causes sexual dysfunction (erectile dysfunction, loss of sex drive, sperm quality damage, testicle damage):
https://journals.lww.com/aidsonline/Fulltext/2001/05250/Sexual_dysfunction_associated_with_protease.10.aspx
https://www.aidsmap.com/news/may-2002/ritonavir-most-strongly-linked-male-sexual-dysfunction
https://www.natap.org/2002/june/060302_2.htm
https://pubmed.ncbi.nlm.nih.gov/15052987/
http://pubs.sciepub.com/ajps/2/5/4/index.html
https://pubmed.ncbi.nlm.nih.gov/26150184/
RITONAVIR causes oxidative stress and nitrosative stress (reactive oxygen species and reactive nitrogen species):
https://academic.oup.com/cardiovascres/article/63/1/168/282509
https://pubmed.ncbi.nlm.nih.gov/17668557/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787040/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841797/
https://www.sciencedirect.com/science/article/abs/pii/S0891584914000240
https://www.researchgate.net/publication/325404037_LopinavirRitonavir_Treatment_Induces_Oxidative_Stress_and_Caspaseindependent_Apoptosis_in_Human_Glioblastoma_U-87_MG_Cell_Line
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358897/
https://www.mdpi.com/1422-0067/19/8/2409/htm
RITONAVIR causes insulin resistance (new-onset diabetes):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167072/
https://pubmed.ncbi.nlm.nih.gov/24259240/
https://pubmed.ncbi.nlm.nih.gov/10852083/
https://pubmed.ncbi.nlm.nih.gov/10888979/
https://www.sciencedirect.com/science/article/abs/pii/S0166354211004463
https://source.wustl.edu/2010/11/hiv-drugs-interfere-with-blood-sugar-lead-to-insulin-resistance/
RITONAVIR causes pancreatitis (inflammation of the pancreas):
https://link.springer.com/article/10.1007/s100960050194
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111571/
https://academic.oup.com/cid/article/28/1/161/302377
https://www.thebody.com/article/an-overview-of-norvir-ritonavir
RITONAVIR causes endocrine system dysfunction (damage to adrenal glands and other glands):
https://pubmed.ncbi.nlm.nih.gov/21730243/
https://journals.sagepub.com/doi/full/10.1177/2325957414567681
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827556/
RITONAVIR causes lipolysis, lipoatrophy, lipohypertrophy, lipodystrophy (unwanted relocation of body fat), and atherosclerotic lesions:
https://academic.oup.com/cid/article/30/Supplement_2/S135/372084
https://pubmed.ncbi.nlm.nih.gov/14709251/
https://academic.oup.com/jcem/article/90/6/3251/2870553
https://www.ahajournals.org/doi/full/10.1161/01.ATV.0000194073.87647.10
https://journals.sagepub.com/doi/abs/10.3851/IMP2039
https://i-base.info/qa/775
https://pubmed.ncbi.nlm.nih.gov/22297608/
https://www.sciencedirect.com/science/article/abs/pii/S0166354212001040
https://themedicalbiochemistrypage.org/lipolysis-and-the-oxidation-of-fatty-acids/
https://en.wikipedia.org/wiki/Lipoatrophy
https://en.wikipedia.org/wiki/Lipodystrophy#Antiretroviral_drugs
https://en.wikipedia.org/wiki/HIV-associated_lipodystrophy#Presentation
https://duckduckgo.com/?q=lipoatrophy&kp=1&iar=images&iax=images&ia=images
https://duckduckgo.com/?q=lipodystrophy&kp=1&iar=images&iax=images&ia=images
https://duckduckgo.com/?q=lipohypertrophy&kp=1&iar=images&iax=images&ia=images
RITONAVIR causes hair loss (hair follicle damage):
https://pubmed.ncbi.nlm.nih.gov/17763601/
https://escholarship.org/uc/item/0n583197
https://journals.lww.com/aidsonline/fulltext/2007/06190/alopecia_associated_with_ritonavir_boosted.31.aspx
https://journals.lww.com/aidsonline/fulltext/2002/08160/generalized_hair_loss_induced_by_indinavir_plus.21.aspx
RITONAVIR causes hypermenorrhea (excessive menstrual bleeding, new-onset gastrointestinal bleeding)
https://www.proquest.com/docview/199035865
RITONAVIR causes CNS (cental nervous system) dysfunction (nerve damage):
https://penntoday.upenn.edu/news/penn-study-finds-link-between-hiv-treatment-and-neuronal-degeneration
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282963/
RITONAVIR causes intracellular dysfunction (endoplasmic reticulum damage, mitochondria damage):
https://link.springer.com/article/10.1007/s10565-018-09451-7
RITONAVIR and other HIV drugs worsen the gut microbiota (more gas, more diarrhea, and less beneficial, health-protecting, probiotic chemicals):
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0258226
RITONAVIR boosts the amount of toxic metals (arsenic, barium, beryllium, cadmium, lead, and mercury) inside of the human body by potently inhibiting CYP3A4, the most important of the hepatic, drug-metabolizing enzymes:
https://pubmed.ncbi.nlm.nih.gov/25274602/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372271/
https://ars.els-cdn.com/content/image/1-s2.0-S0278691520306992-gr2_lrg.jpg
RITONAVIR causes eryptosis (red blood cell apoptosis):
https://onlinelibrary.wiley.com/doi/10.1111/bcpt.12547
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426644/
https://en.wikipedia.org/wiki/Eryptosis
RITONAVIR causes muscle loss (muscle damage):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524660/
https://pubmed.ncbi.nlm.nih.gov/15090791/
RITONAVIR causes bone loss (bone damage):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838480/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368553/
https://www.frontiersin.org/articles/10.3389/fphys.2018.01074/full
https://pubmed.ncbi.nlm.nih.gov/25948863/
https://journals.lww.com/aidsonline/Fulltext/2002/07260/Ritonavir_associated_hyperparathyroidism,.19.aspx
https://www.natap.org/2008/CROI/croi_104.htm
https://www.thebodypro.com/article/bone-loss-similar-among-patients-taking-lopinavir-ritonavir-efavi
RITONAVIR causes hypertension (high blood pressure):
https://journals.lww.com/aidsonline/Fulltext/2006/04240/Antiretroviral_medications_associated_with.9.aspx
https://www.aidsmap.com/news/apr-2006/starting-treatment-kaletra-involves-greater-risk-increased-blood-pressure-linked-gain
https://www.aidsmap.com/news/dec-2006/severe-interaction-between-low-dose-ritonavir-and-blood-pressure-drug-observed
https://www.medpagetoday.com/opinion/skeptical-cardiologist/96692
RITONAVIR causes cognitive dysfunction (brain damage):
https://www.thebody.com/article/protease-inhibitors-linked-to-cognitive-decline-wh
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400265/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474176/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225305/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086755/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164642/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991583/
http://www.prn.org/index.php/complications/article/neurologic_complications_hiv_antiretroviral_therapy_75
RITONAVIR penetrates the blood-brain barrier and remains trapped in the brain’s capillaries:
https://pubmed.ncbi.nlm.nih.gov/14634041/
https://pubmed.ncbi.nlm.nih.gov/31209776/
RITONAVIR causes hyperlipidemia and hypertriglyceridemia (blood cholesterol ratio damage):
https://academic.oup.com/cid/article/38/7/1017/320836
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392175/
RITONAVIR causes gingivitis (worsens gum health):
https://onlinelibrary.wiley.com/doi/10.1111/j.1468-1293.2010.00863.x
RITONAVIR causes cardiovascular dysfunction (heart damage):
https://www.contagionlive.com/view/ritonavir-boosted-protease-inhibitors-may-increase-risk-of-cardiovascular-disease-death
https://advances.massgeneral.org/cardiovascular/article-external.aspx?id=1033
https://www.sciencedirect.com/science/article/pii/S092544391300344X
https://ars.els-cdn.com/content/image/1-s2.0-S092544391300344X-gr2_lrg.jpg
https://www.thecardiologyadvisor.com/home/topics/arrhythmia/ritonavir-may-increase-the-risk-for-bradycardia-in-covid-19/
https://www.healio.com/news/cardiology/20200724/treatment-of-covid19-with-lopinavirritonavir-may-raise-bradycardia-risk
https://www.jacc.org/doi/full/10.1016/j.jacc.2018.04.083
https://ars.els-cdn.com/content/image/1-s2.0-S0735109718349970-gr6.jpg
https://www.natap.org/2012/images/072312/072312-5/adverse2.gif
https://www.infectiousdiseaseadvisor.com/home/topics/hiv-aids/cumulative-ritonavir-boosted-darunavir-use-may-be-associated-with-increased-cvd-risk/
https://journals.physiology.org/doi/full/10.1152/ajpregu.00268.2013
https://journals.lww.com/aidsonline/Fulltext/2017/11280/Switching_from_a_ritonavir_boosted_protease.8.aspx
https://www.umcvc.org/health-library/d04717a1
https://www.internationaljournalofcardiology.com/article/S0167-5273(20)33981-4/fulltext
RITONAVIR can reactivate hepatitis B or hepatitis C in people who have already been exposed to these 2 hepatitis viruses in the past:
https://pbs.twimg.com/media/CodczKiWIAACzYO.jpg:large
https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/data-and-trends/index.html
https://www.ncbi.nlm.nih.gov/books/NBK548301/
RITONAVIR causes hepatic steatosis (fatty liver disease):
https://www.sciencedirect.com/science/article/abs/pii/S0024320518306404
https://ars.els-cdn.com/content/image/1-s2.0-S0024320518306404-ga1_lrg.jpg
https://www.mdpi.com/cells/cells-10-01687/article_deploy/html/images/cells-10-01687-g001.png
https://www.wjgnet.com/1007-9327/full/v26/i32/WJG-26-4753-g001.htm
https://www.researchgate.net/figure/FXR-and-PPAR-a-ligands-attenuate-liver-steatosis-induced-by-the-HIV-protease-inhibitor_fig10_47430514
https://www.researchgate.net/figure/Exposure-to-ritonavir-causes-SREBP1c-activation-in-the-liver-and-monocytes-In_fig8_47430514
https://pubmed.ncbi.nlm.nih.gov/31219362/
https://pubmed.ncbi.nlm.nih.gov/32490327/
https://twitter.com/hepcommjournal/status/1295692323033174016/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597219/
RITONAVIR causes renal calculi or nephrolithiasis (kidney stones that are composed of pure ritonavir):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605930/
https://www.sciencedirect.com/science/article/pii/S2214442021002035
https://www.consultant360.com/articles/protease-inhibitor-induced-nephrolithiasis
https://www.empr.com/home/news/stone-formation-in-an-hiv-patient-two-years-after-stopping-ritonavir/
https://speciality.medicaldialogues.in/hiv-patient-develops-ritonavir-induced-kidney-stone-2-years-after-stopping-it-bmj-case-report
RITONAVIR causes renal dysfunction (kidney damage):
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)65125-2/fulltext
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727453/
https://journals.lww.com/aidsonline/Fulltext/2020/06010/HIV_protease_inhibitor_ritonavir_induces_renal.3.aspx
https://www.kireports.org/article/S2468-0249(20)31434-0/fulltext
https://journals.lww.com/aidsonline/Fulltext/2014/03130/Antiretrovirals_and_the_kidney_in_current_clinical.1.aspx
https://www.natap.org/2016/images/010616/010616-1/HIV1.gif
https://academic.oup.com/jid/article/207/9/1349/929238
https://journals.lww.com/aidsonline/fulltext/2015/02200/acute_interstitial_nephritis_caused_by.12.aspx
NIRMATRELVIR causes even more renal dysfunction (kidney damage) than ritonavir:
https://www.ismp.org/alerts/medication-safety-issues-newly-authorized-paxlovid
https://www.healthnavigator.org.nz/paxlovid/
PAXLOVID or RITONAVIR (swallowed alone) can sometimes cause hives (skin rash):
https://academic.oup.com/jac/article/62/5/879/722729
https://pubmed.ncbi.nlm.nih.gov/24507978/
https://pubmed.ncbi.nlm.nih.gov/15757820/
https://elsevier.health/en-US/preview/nirmatrelvir-ritonavir-oral-tablets-paxlovid
https://en.wikipedia.org/wiki/Hives#/media/File:EMminor2010.JPG
PAXLOVID or RITONAVIR (swallowed alone) always causes a bitter, metallic taste:
https://www.wikidoc.org/index.php/Ritonavir_description
https://pubmed.ncbi.nlm.nih.gov/10501290/
https://www.yahoo.com/entertainment/heres-why-many-people-talking-165700302.html
PAXLOVID can sometimes cause dysgeusia (loss or alteration of taste):
https://medicalxpress.com/news/2022-05-covid-affected-paxlovid-mouth-disgusting.html
PAXLOVID is a nightmare for organ transplant recipients, for whom Paxlovid is frequently prescribed because they qualified for it by being “high-risk” for bad outcomes from COVID-19:
https://www.medpagetoday.com/transplantation/transplantation/98708
We’ll see if Pfizer, Shionogi, Enanta, Todos, Zhongsheng, and Simcere can live up to their exaggerated claims after the bad side effects and inadequate efficacies of their protease inhibitors are first discovered in unauthorized foreign research studies:
https://www.frontiersin.org/files/Articles/616595/fimmu-11-616595-HTML/image_m/fimmu-11-616595-g001.jpg
Dozens of 3CL protease inhibitors have been discovered, ranging from very safe (vitamin B12) to poorly tolerated (cancer chemotherapy drugs):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062204/
https://www.researchgate.net/publication/339417253/figure/tbl2/AS:861196089577472@1582336556237/Possible-side-effects-and-routes-of-administration-of-the-drugs-identified-from-virtual.png
https://pubs.acs.org/doi/10.1021/acsptsci.0c00108
HIV-1 protease inhibitors for treating human immunodeficiency virus (HIV) are highly vulnerable to drug resistance:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912444/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772045/
https://www.medicalnewstoday.com/articles/323872#side-effects
https://hivdb.stanford.edu/dr-summary/resistance-notes/PI/
NS3/4A protease inhibitors for treating hepatitis C virus (HCV) are highly vulnerable to drug resistance:
https://www.sciencedirect.com/science/article/pii/S0168827811000791
3CL proteae inhibitors, including nirmatrelvir, are highly vulnerable to drug resistance:
https://www.biorxiv.org/content/10.1101/2022.06.07.495116v1.full
https://www.biorxiv.org/content/10.1101/2022.06.06.494921v1.full
https://www.biorxiv.org/content/10.1101/2022.06.28.497978v1.full
https://www.news-medical.net/news/20220630/SARS-CoV-2-can-evade-Paxlovid-by-multiple-mechanisms.aspx
https://www.coronaheadsup.com/health/treatment/paxlovid/science-mag-sars-cov-2-already-finding-ways-to-evade-paxlovid/
https://www.biorxiv.org/content/10.1101/2022.07.02.495455v1.full
https://www.news-medical.net/news/20220706/Paxlovid-resistance-associated-with-SARS-CoV-2-3CLpro-mutations.aspx
https://www.biorxiv.org/content/10.1101/2022.07.12.499687v1.full
However, RNA-dependent RNA polymerase (RdRp) inhibitors (favipiravir, ribavirin) are less likely to encounter viral drug resistance. Ribavirin, which was invented in 1972, continues to be used today to treat hepatitis C virus (HCV) patients:
https://www.antimicrobe.org/drugpopup/ribavirin.htm
Although most governments have been eager to purchase and try both Paxlovid and molnupiravir, the demand among the people for these 2 poorly tested antivirals has been unexpectedly low. This has forced the US FDA to extend the shelf life of Paxlovid to prevent huge quantities of this expensive (inflationary) drug from being discarded into the trash can by pharmacists:
https://publications.aap.org/aapnews/news/19938/FDA-extends-shelf-life-of-COVID-antiviral-Paxlovid
https://www.theglobeandmail.com/canada/article-covid-19-antiviral-drug-paxlovid-being-dispensed-at-low-rates-across/
https://www.npr.org/sections/health-shots/2022/03/18/1087380770/lifesaving-covid-drugs-are-sitting-unused-on-pharmacy-shelves-hhs-data-shows
https://www.sfchronicle.com/health/article/S-F-health-officials-return-thousands-of-17062896.php
https://www.cidrap.umn.edu/news-perspective/2022/02/eagerly-awaited-covid-lifesavers-molnupiravir-paxlovid-now-wait-patients
https://www.citizensvoice.com/news/coronavirus/anti-covid-19-pills-more-available-but-demand-down/article_13d8228e-e2e8-5495-a369-6611a514617c.html
https://timesofindia.indiatimes.com/city/nagpur/experts-divided-over-use-of-molnupiravir-low-demand-for-drug/articleshow/88818929.cms
https://www.wsj.com/articles/highly-touted-monoclonal-antibody-therapies-sit-unused-in-hospitals-11609087364
https://www.bridgemi.com/michigan-health-watch/why-stockpile-promising-covid-19-treatment-sits-unused-lansing
https://www.freep.com/story/news/health/2022/04/11/covid-19-antiviral-treatments-monoclonal-antibodies-unused-michigan/9512596002/
https://abc7chicago.com/paxlovid-side-effects-availability-covid-pill-interactions/11738642/
https://www.cbc.ca/news/canada/calgary/paxlovid-covid-transmission-grows-alberta-1.6417098
https://sports.yahoo.com/thousands-covid-19-treatments-sit-100015838.html
https://www.nzdoctor.co.nz/article/news/covid-antiviral-uptake-lower-expected
https://www.dailymail.co.uk/health/article-10719697/Nearly-600-000-course-Pfizers-Paxlovid-sitting-UNUSED-America.html
https://www.reuters.com/business/healthcare-pharmaceuticals/demand-pfizers-covid-pills-lags-around-world-2022-04-19/
https://www.kpbs.org/news/midday-edition/2022/04/18/supplies-of-covid-19-antiviral-pill-paxlovid-are-abundant-as-demand-lessens
https://www.fiercepharma.com/pharma/pfizers-covid-19-antiviral-paxlovid-hits-worldwide-demand-slump
https://seekingalpha.com/news/3824295-demand-for-pfizer-covid-19-antiviral-paxlovid-not-as-high-as-expected-reuters
https://newyork.forumdaily.com/en/pakslovid-ot-pfizer-nazyvali-proryvom-v-lechenii-covid-19-kuda-ischez-etot-preparat-obeshhavshij-stat-revolyucionnym/
https://www.khmertimeskh.com/501060021/sharp-drop-in-molnupiravir-use-as-infections-get-milder/
https://www.union-bulletin.com/seattle_times/why-aren-t-doctors-prescribing-anti-covid-medicines/article_57d827a9-6b18-5b43-b483-f9afaf7208d6.html
https://adnamerica.com/en/united-states/pfizers-covid-19-pill-supply-outstrips-demand
https://www.ruetir.com/2022/04/21/antiviral-paxlovid-from-the-family-doctor-bassetti-yet-another-thing-done-wrong/
https://www.medrxiv.org/content/10.1101/2022.04.21.22274155v1
https://fox59.com/news/coronavirus/indiana-providers-prescribing-paxlovid-to-handful-of-covid-19-patients/
https://www.ctinsider.com/news/article/CT-has-12-000-free-Paxlovid-doses-to-treat-COVID-17157429.php
https://www.taipeitimes.com/News/editorials/archives/2022/05/15/2003778210
https://www.fool.com/investing/2022/05/17/pfizers-setbacks-with-paxlovid-are-mounting-should/
https://pbswisconsin.org/news-item/wisconsins-covid-condition-antiviral-use-low-as-another-omicron-wave-builds/
https://www.irishtimes.com/news/health/only-65-doses-of-covid-antiviral-pill-administered-to-irish-patients-1.4882251
https://www.irishtimes.com/health/2022/06/13/fewer-than-170-doses-of-game-changer-covid-19-drug-given-to-irish-patients/
https://www.surinenglish.com/spain/spain-pfizer-covid-treatments-20220606173736-nt.html
https://www.fox5vegas.com/2022/06/14/not-enough-people-sick-with-covid-19-getting-eligible-medications-snhd-says/
https://carolinapublicpress.org/54665/covid-19-medications-widely-available-in-nc-but-how-are-they-being-used/
https://www.news-medical.net/news/20220616/At-a-Bay-Area-e28098test-to-treate28099-site-few-takers-for-free-antivirals.aspx
https://khn.org/news/article/covid-antiviral-community-test-to-treat-berkeley-california/
https://prress.com/health/covid-antivirals-paxlovid-does-not-even-take-off-in-the-pharmacy-in-a-month-only-2-thousand-treatments/
Merck recently reminded us that ritonavir-boosted protease inhibitors, including Pfizer’s Paxlovid, have the longest list of bad drug interactions of any drugs in history. Although both nirmatrelvir and ritonavir are pro-oxidants that will damage every cell in the human body if used longer than 5 days, ritonavir causes 621 out of the 627 bad drug interactions caused by Paxlovid, while ritonavir causes 221 out of the 227 “major” bad drug interactions caused by Paxlovid:
https://www.ft.com/content/7ded2361-e797-465e-ac25-a42c1d899881
https://www-echo24-de.translate.goog/welt/paxlovid-corona-medikament-probleme-wechselwirkung-wirkstoffe-studien-ritonavir-91378715.html?_x_tr_sl=de&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
https://twitter.com/absteward/status/1476758865790259205
https://www.drugs.com/drug-interactions/paxlovid-with-remdesivir-4326-19915-4146-0.html
https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/management-of-drug-interactions-with-nirmatrelvirritonavir-paxlovid/
https://www.sciencedirect.com/science/article/pii/S0040595722000658
https://www.drugs.com/drug-interactions/remdesivir.html
https://www.drugs.com/drug-interactions/ritonavir.html
https://www.drugs.com/drug-interactions/nirmatrelvir-ritonavir,paxlovid.html
In their zeal to dispense Paxlovid, proper vetting for Paxlovid’s 627 bad drug interactions isn’t being done:
https://news.bloomberglaw.com/health-law-and-business/pfizer-covid-pill-access-stymied-by-vague-prescribing-guidance
https://www.pharmacypracticenews.com/Covid-19/Article/07-22/ISMP-Issues-Warning-About-Paxlovid-Errors/67406
https://academic.oup.com/cid/article/37/5/e72/312798
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085857/
Many people say that their COVID-19 viral load and symptoms got better, then worse, after swallowing Paxlovid:
https://www.coronaheadsup.com/health/treatment/paxlovid/paxlovid-covid-19-infections-rebounding-a-few-days-after-treatment/
https://www.bostonglobe.com/2022/04/21/metro/puzzling-phenomenon-patients-report-rebound-covid-19-symptoms-after-taking-antiviral-paxlovid/
https://www.dailymail.co.uk/health/article-10744285/Recipients-Paxlovid-report-symptoms-returning-testing-positive-virus-again.html
https://twitter.com/DrEricDing/status/1517338915031683072/
https://www.realclearscience.com/2022/04/23/the_paxlovid_rebound_problem_is_real_828595.html
https://www.acsh.org/news/2022/04/26/covid-rebound-following-paxlovid-therapy-should-we-worry-16272
https://www.slashgear.com/845448/covid-19-is-recurring-in-patients-who-took-pfizers-antiviral-doctors-dont-know-why/
https://news.yahoo.com/covid-symptoms-may-return-taking-143245890.html
https://heromag.net/another-rare-virus-puzzle-they-got-sick-got-treated-got-covid-again
https://www.sciencetimes.com/articles/37379/20220428/covid-19-reinfects-people-who-took-pfizer-antivirus-treatment.htm
https://www.bloomberg.com/news/articles/2022-04-29/u-s-seeks-urgent-data-on-covid-relapses-after-pfizer-drug
https://twitter.com/EricTopol/status/1519664698865508353/
https://blogs.jwatch.org/hiv-id-observations/index.php/more-on-relapses-after-paxlovid-treatment-for-covid-19/2022/05/04/
https://twitter.com/DrEricDing/status/1521723944851714048/
https://twitter.com/DrEricDing/status/1522024332427509761/
https://pbs.twimg.com/media/FR9REDUX0AMclxY.jpg:large
https://rumble.com/v13se1n-pfizer-ceo-commits-federal-crimes-peddling-paxlovid-off-label.html
https://www.statnews.com/2022/05/24/paxlovid-rebound-has-covid-researchers-looking-for-theories/
https://theskepticalcardiologist.com/2022/06/13/rebound-symptoms-after-paxlovid-for-covid-19-many-cases-and-many-unanswered-questions/
https://www.yahoo.com/entertainment/fauci-says-experienced-paxlovid-rebound-200935592.html
Reports are emerging of the restarting of full-fledged COVID-19 among people who swallowed Paxlovid:
https://news.yahoo.com/covid-19-mystery-getting-coronavirus-143757835.html
In his 5-31-2022 study, Dr. Michael Charness of the VA Medical Center in Boston warns that Paxlovid swallowers can still be superspreaders, even if if they were among the 10% to 20% of Paxlovid swallowers who tested false negative on Day 2:
https://www.forbes.com/sites/madelinehalpert/2022/05/31/rebound-covid-infections-some-contagious-even-after-taking-antiviral-paxlovid-paper-suggests/
https://journalstar.com/townnews/medicine/coronavirus-can-be-contagious-during-a-paxlovid-rebound-researchers-warn-even-if-people-dont-have/article_cedc74cb-c554-5596-b0c4-95011d34645b.html
Pfizer wants to block all scientific studies that they don’t control with their billions of dollars in bribe money. Pfizer especially fears scientific studies that force Paxlovid to be compared in efficacy against molnupiravir, favipiravir, or Shionogi’s Xocova (ensitrelvir):
https://c19early.com/ledford.html
https://pubmed.ncbi.nlm.nih.gov/35379975/
https://www.bnnbloomberg.ca/pfizer-s-tight-paxlovid-rein-stymies-drug-combination-research-1.1767525
Here’s the truth about Paxlovid in Hong Kong, which first received Paxlovid on 3-14-2022, which is AFTER their Omicron wave had nearly ended:
https://www.info.gov.hk/gia/general/202203/15/P2022031500280.htm
By 4-23-2022, Hong Kong’s Omicron wave had ended:
https://www.google.com/search?q=hong+kong+covid-19+cases
Hong Kong reported on 4-23-2022 that almost nobody had been prescribed Paxlovid between 3-14-2022 and 4-23-2022, when Paxlovid was, and still is, in abundant oversupply:
https://www.scmp.com/news/hong-kong/health-environment/article/3175289/hong-kong-health-authorities-report-few-patients
In the Pfizer-funded, Hong Kong clinical trial by Cheuk Fung Yip, molnupiravir had 17% more hospitalizations than the control group, while Paxlovid had only 21% less hospitalizations than the control group, not 89% less hospitalizations than the control group as Pfizer had been claiming:
https://twitter.com/emlitofnote/status/1528860784201461761/
https://pbs.twimg.com/media/FTeZ96JagAAF53t.jpg:large
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4112160
“Conclusion: Both antivirals did not reduce the risk of COVID-19-associated ventilator use, ICU occupancy, or death:”
https://timetotimes.com/the-effectiveness-of-molnupiravir-and-nirmatrelvir-ritonavir-in-reducing-hospitalization-and-deaths-in-non-hospitalized-covid-19-patients/
https://c19mp.com/yip.html
https://c19early.com/yip.html
https://c19early.com/yippl.html
In the Pfizer-funded, Israeli clinical trial by Ronen Arbel, in the 40-to-64 age bracket, Paxlovid had only 22% less hospitalizations than the control group, not 89% less hospitalizations than the control group as Pfizer had been claiming. In the 40-to-64 age bracket, Paxlovid INCREASED mortality by 64%:
https://www.israelnationalnews.com/news/354306
Of the 42,819 Israelis over age 65 who were eligible, only 2,504 of them, or 5.85% of them, agreed to swallow the Paxlovid pills, while 94.15% of these 42,819 Israelis refused.
Of the 66,394 Israelis aged 40-to-64 who were eligible, only 1,435 of them, or 2.16% of them, agreed to swallow the Paxlovid pills, while 97.84% of these 66,394 Israelis refused.
“and even those in the older [65-plus age] group who were vaccinated or recovered saw [only] a relatively small benefit from Paxlovid:”
https://www.washingtonpost.com/business/doctors-are-still-flying-blind-with-paxlovid/2022/06/03/5157e924-e331-11ec-ae64-6b23e5155b62_story.html
https://c19early.com/arbel.html
On 5-24-2022, Shanghai Junshi Biosciences reported that their nucleoside analog (RdRp inhibitor), VV116 (JT001), defeated the 3C-like protease (3CLpro) inhibitor, Paxlovid, in a Phase 3 clinical trial. The VV116 molecule is more similar to the molecule of Gilead Sciences’ GS-441524 than to the molecules of the nucleoside analogs, ribavirin, favipiravir, or molnupiravir:
https://finance.yahoo.com/news/vv116-versus-paxlovid-phase-iii-032200973.html
In India, on 1-12-2022, the Indian Council of Medical Research (ICMR) dropped molnupiravir from India’s national treatment protocol for COVID-19:
https://timesofindia.indiatimes.com/india/icmr-reiterates-concerns-on-molnupiravir-use-in-covid-treatment/articleshow/88860355.cms
In India, on 5-7-2022, the Indian Council of Medical Research (ICMR) dropped Paxlovid from India’s national treatment protocol for COVID-19:
https://medicaldialogues.in/news/industry/pharma/paxlovid-not-be-included-in-national-treatment-guidelines-for-covid-19-says-icmr-92587
*****************